肾病综合征患者血和尿中PAI-1的变化及其临床意义

目的 探讨肾病综合征患者血、尿PAI-1浓度的改变及其与疾病的关系。方法 分为正常对照组、肾病综合征组，采集激素治疗前后血浆和尿液标本用ELISA法检测PAI-1的含量，速率散射比浊法测定尿清蛋白，常规生化方法检测肾功能。结果 肾病综合征组血、尿PAI-1含量升高（P〈0．05），血浆和尿液中PAI-1与尿清蛋白浓度无明显相关性（r=0．247，0．234，P〉0．05），尿液PAI-1和血肌酐值呈正相关（r=0．37，P〈0．05）。激素治疗后比治疗前PAI-1水平降低。结论 PAI-1在肾病综合征的发生发展中起重要作用。

Alterations of Plasma and Uric PAI-1 in Nephrotic Syndrome Patients

Objective To measure the plasma and urine levels of plasmimogen activitor inhibitor 1 type(PAI-1)in nephrotic syndrome(NS)patients and to study their clinical significance.Methods Patients were divided into groups of normal con- trol and NS.ELISA was used to measure concentration of PAI-1 in pre-treatment and post-treatment,rate nephelometry was used to detect the M-Alb in urine and clinical chemistry assay was used to measure kidney function.Results The plasma and urine levels of PAI-1 in NS group was significantly higher than that of normal control(P<0.05).There was no significant correlation between levels of PAI-1 and M-Alb in urine and plasma(r=0.247,0.234,P>0.05),and the urine levels of PAI-1 was positively correlated with degree of the serum creatinine(r=0.37,P<0.05).The concentration of PAI-1 decreased compared to the group of pre-treatment.Conclusion PAI-1 can reflect damage of renal of nephritic syn- drome.